Siglec-15 Is a Novel Immunomodulatory Protein and Therapeutic Target in Acute Lymphoblastic Leukemia

Claire E. Pillsbury,Jairo A. Fonseca,Jodi Dougan,Hasan Abukharma,Gloria Gonzalez-Flamenco,Sunita I. Park,Linda N. Liu,Christopher C. Porter

BLOOD（2021）

引用 2|浏览7

暂无评分

摘要

Immunotherapies have recently shown efficacy in treatment of aggressive, refractory pediatric B cell acute lymphoblastic leukemia (B-ALL), which remains one of the leading causes of cancer-related death in children. The immune evasion mechanisms of B-ALL are still being explored to discover new therapeutic targets and improve patient outcomes.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要